Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Stopped The study was stopped due to the inability to determine an acceptable dose with the potential for further study
Conditions
- Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Primary Peritoneal Neoplasm
Interventions
- BIOLOGICAL: KHK2866
- DRUG: Gemcitabine and Carboplatin
- DRUG: paclitaxel
- DRUG: pegylated liposomal doxorubicin
Sponsor
Kyowa Kirin Co., Ltd.
Collaborators